Allergies are characterized by inappropriate inflammatory responses to benign environmental antigens. Primary clinical approaches to allergic disease consist of symptom control or administration of soluble antigens to skew the immune response to alternate phenotypes or induce immune tolerance. However, such approaches carry a significant risk of adverse events and require a long treatment course to achieve efficacy. Now, a study from![]()
